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The intestinal milieu harbours the gut microbiota, consisting of a complex community 
of bacteria, archaea, fungi, viruses and protozoans that bring to the host organism an 
endowment of cells and genes more numerous than its own. In recent years, an interest 
in intestinal microbiota-host interactions has increased due to many findings about the 
impact of gut bacteria on human health and disease. Gut microbiota dysbiosis, defined 
as marked alterations in the amount and function of the intestinal microorganisms, is 
correlated with the aetiology of chronic diseases, ranging from cardiovascular, neurologic, 
respiratory and metabolic illnesses to cancer. In this review, we focus on the interplay 
among gut microbiota and host to provide a perspective on the role of microbiota in the 
pathogenesis and progression of various human disorders, highlighting the influence of 
gut microbiota on cancers in the gastrointestinal tract and on neurodegenerative diseases.
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Background
The human is a superorganism that functions in harmony 
with trillions of symbiotic bacteria and eukaryotic cells. 
Human normal microorganism are mainly distributed 
in the internal cavity of the body, such as respiratory, 
digestive and urogenital tract, and body surface forming 
four microecosystem.[1] Of these four site, the gut 
microbiota has drawn the attention of the scientific 
community for its clinical significance, and it is now well 
established that a healthy gut flora is largely responsible 
for overall health of the host[2]. It has been shown that 
an imbalance in the gut microbiota, called dysbiosis, is 
associated with various diseases, ranging from intestinal 
diseases, like gastric and colorectal cancer, irritable 
bowel syndrome, and inflammatory bowel disease[3], 
to other systemic diseases and to central nervous 
system (CNS) diseases, such as multiple sclerosis (MS) 
and amyotrophic lateral sclerosis (ALS).[4] Here, we 
mainly reviewed the influence of gut microbiota on two 
different fields, cancers in the gastrointestinal (GI) tract 
and neurodegenerative diseases. 
The gut microbiota
The human gut microbiota consists of several types of 
microbes including bacteria, archaea, eukarya, viruses 
and parasites. In recent years, the Metagenomics of 
the Human Intestinal Tract (MetaHIT) and the Human 
Microbiome Project (HMP) have provided the most 
integrated view of human-associated microbes. Hugon 
et al. listed 2172 species isolated in human, which they 
classified into 12 different phyla, and among these 
divisions, the Bacteroidetes and the Firmicutes constitute 
more than 90% of the total population.[5] Traditionally, 
the Firmicutes: Bacteroidetes ratio has been implicated in 
predisposition to disease state; however, the significant 
variability even in healthy individuals that has been 
observed across recent studies makes the relevance of 
this ratio debatable.[6]
Microbiota is acquired at birth and develops in parallel 
with the host playing an important role in maintaining 
the body healthy through adulthood until death. After 
birth, microbes rapidly colonize the sterile neonatal GI 
tract, and the microbiota composition partially depends 
on the delivery mode and whether breast-feeding is 
done.[7] The intestines of infants born vaginally are 
initially colonized by organisms from the maternal 
vagina, organisms from the genera Lactobacillus and 
Prevotella, on the contrary in cesarean delivery mostly 
the maternal skin flora colonizes the infant’s intestine 
with the dominance of Streptococcus, Corynebacterium 
and Propionibacterium.[8] Thereafter by the age of 
3-5 years, the unstable structure and composition of 
microbiota starts to differentiate and gradually develops 
to resemble that of adults. In adulthood, the composition 
and functions of the established microbiota remain the 
same if there is no change in long-term dietary habits, 
antibiotics treatment, stress and pathophysiology 
in adulthood.[9] Indeed, recent evidence has shown 
that the adult microbiome is not stable as previously 
believed, and there are many important endogenous and 
exogenous factors for the composition of the intestinal 
microbial community, such as genetic factors, sex, 
dietary habits and food types, drugs and other factors 
including lifestyle, illness, smoking and drug addiction1.
The gut microbiota, which derives its nutrient from 
host dietary components and shed epithelial cells, 
is an organ by itself with an extensive metabolic 
capability and substantial functional plasticity. The 
normal gut microbiota imparts specific function in host 
nutrient metabolism, xenobiotic and drug metabolism, 
maintenance of structural integrity of the gut mucosal 
barrier, immunomodulation and protection against 
pathogens.[6] On the contrary, a shift in the balance 
of microbiota composition such that it may become 
deleterious to host health is termed dysbiosis. Dysbiosis 
of the gut microbiome has been implicated in numerous 
disorders, ranging from intestinal diseases, to more 
systemic disease and neurological disorders.[10]
Gut microbiota and gastrointestinal cancer
In the past decade, the interaction between 
microorganisms and tumors have attracted much 
attention in the efforts understand the possible 
mechanisms through which the microbiota is involved in 
cancer prevention, carcinogenesis and therapy. Various 
studies have demonstrated that impaired microbiota 
can facilitate carcinogenesis via multiple pathways, and 
further studies have suggested that the microbiota and 
his associated metabolites are not only closely related to 
carcinogenesis by inducing inflammation and immune 
dysregulation, which lead to genetic instability, but 
also interfere with the pharmacodynamics of anticancer 
agents.[11] The link has been found both with local 
gastro-intestinal cancers, as well as with other distal 
tumors.[12]
The most well established risk factor for gastric cancer 
(GC) is Helicobacter pylori infection.[13] Infection 
by H. pylori can stimulate immune responses and 
inflammation, regulate many signaling pathways, and 
induce achlorhydria, epithelial atrophy and dysplasia.
[14] Furthermore, H. Pylori also indirectly promotes 
carcinogenesis by changing the composition of the 
gastric microbiota. Several studies showed the gastric 
microbiota arose from patients infected with H. Pylori 
are different from uninfected people, suggesting an 
interaction between H. Pylori and gastric microbial 
community. Though the mechanism of H. Pylori in 
altering the gastric microbiota remain unclear, all of 
these findings had shed a light that dysbiosis of gastric 
microbiota might related to the susceptibility to gastric 
inflammation and tumorigenicity in patients with H. 
pylori infection.[15] 
Various factors contribute to colorectal cancer (CRC) 
and the involvement of the microbiota in colorectal 
carcinogenesis is becoming increasingly clear. Indeed, 
many changes in the bacterial composition of the gut 
microbiota have been reported in CRC, suggesting a 
major role of dysbiosis in colorectal carcinogenesis.
[16,17] Some bacterial species have been identified 
and suspected to play a role, these species primarily 
include Streptococcus bovis, H. pylori, Bacteroides 
fragilis, Enterococcus faecalis, Clostridium septicum 
and Escherichia coli.[18] Two different hypotheses have 
emerged to explain contribution of gut microbiota to 
CRC: the presence of a dysbiotic microbial community 
with pro-carcinogenic features capable of remodeling 
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the microbiome as a whole to drive pro-inflammatory 
responses and epithelial cell transformation, and the 
“driver-passenger” theory, where intestinal bacteria, 
termed “bacteria drivers”, initiate CRC by inducing 
epithelial DNA damage and tumorigenesis, in turn 
promoting the proliferation of passenger bacteria that 
have a growth advantage in tumor microenvironment.
[18]
Gut microbiota and neurodegenerative diseases
At the end of the 19th century, the American scientist 
Gershon first described the concept of gut-brain 
connection. Insights into the gut-brain crosstalk have 
revealed a complex communication system that not 
only ensures the proper maintenance of gastrointestinal 
homeostasis, but is likely to have multiple effects on 
affect, motivation and higher cognitive functions. 
The complexity of these interactions is enclosed in the 
denomination of “gut-brain-axis” (GBA).[19] The GBA 
consists of bidirectional communication between the 
central and the enteric nervous system (ENS), and both 
clinical and experimental evidence suggest that gut 
microbiota has an important impact on GBA interacting 
not only with intestinal cells and ENS, but also directly 
with the central nervous system (CNS) through 
neuroendocrine and metabolic pathways.[20] 
The gut microbiota can affect the body’s nervous 
system function in numerous ways, the principal one 
likely being modulation of the intestinal barrier and 
tight junction integrity. Furthermore, microbiota can 
influence ENS activity by production, expression and 
turnover of neurotrasmitters (serotonin, GABA) and 
neurotrophic factor (BDNF), can interact with GBA 
through the modulation of afferent sensory nerves, and 
can affects mucosal immune activation.[19] At the same 
time, the CNS can directly impact the gut via sympathetic 
nervous system or parasympathetic nervous system by 
the secretion of catecholamines or acetylcholine, which 
influence ENS circuits.[1]
Given the impact the microbiota has on the development 
of immune cells and the nervous system, it is possible 
that this microbial interaction may significantly 
influence the course of autoimmune CNS diseases such 
as MS.[21] In the last few years, several studies have 
demonstrated that patients with MS exhibit gut microbial 
dysbiosis with both enrichment and depletion of certain 
bacterial populations compared with healthy controls. 
Modifications of the intestinal environment induced 
by either diet or microbiota composition have been 
linked to the pathogenesis of MS, but the mechanisms 
underlying this association are still largely unknown. 
T helper 17 (TH17) cells are key players in MS: effector 
TH17 cells represent the first wave of pathogenic T cell 
infiltrating the CNS because of their ability to efficiently 
breach the blood-brain barrier, and several studies 
demonstrated that effector TH17 cells that trigger brain 
autoimmunity originate in the intestine.  TH17 cell 
differentiation in the small intestine is regulated by the 
whole microbial community composition and also by 
some specific bacteria. MS patients which high disease 
activity and increased intestinal TH17 cells, frequently 
show a higher Firmicutes: Bacteroidetes ratio with an 
increase in Streptococcus and a decrease in Prevotella 
strains compared to healthy controls and MS patient 
with no disease activity.[22]
ALS belong to neurodegenerative diseases characterized 
by the loss of motor neurons. To date, the pathogenesis of 
ALS remains unclear and is likely multifactorial, and the 
pathophysiology may be related to the gastrointestinal 
tract.[23] Indeed, as widely reviewed by McCombe et 
al., theoretical reasons support the hypothesis of the 
involvement of gut microbiota in the pathogenesis of ALS, 
including connections with the impaired metabolism, 
host immunity, and production of toxins that induce 
brain damage.[24] Most of the experimental evidence of 
gut dysbiosis comes from studies on mouse models for 
ALS. In the G93A-SOD1 transgenic mice models for ALS, 
it was shown that the impaired intestinal epithelium and 
tight junction potentially contributed to the progression 
of ALS, and that replenishment of probiotics and the 
relevant metabolites thereof ameliorated the motor 
ability of mice.[25] In general, a few studies have been 
performed on human ALS, and with conflicting results. 
Brenner et al., and similarly Rowin et al., showed a low 
diversity of intestinal microbial composition in fecal 
samples of ALS compared to controls, inferring that 
there is no direct and significant gut microbiota–disease 
correlation.[24] Conversely, Mazzini et al. highlighted an 
altered ALS gut microbiota by quantitative PCR analysis. 
Specifically, the authors showed a cluster distinction 
between bacterial profiles of ALS patients compared to 
controls, especially related to an increase of Escherichia 
coli and Enterobacteria, and a decrease of Clostridium 
and yeast.[26] Fecal microbiota transplantation (FMT) 
has emerged as a promising strategy to restore gut 
microbiota dysbiosis involved in complex pathologies 
including neurodegenerative diseases. To this regard, 
a very recent paper has proposed a multicenter 
randomized double-blind clinical trial employing FMT 
as a therapeutic intervention for ALS patients at an 
early stage, opening new avenues for the treatment of 
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